Business
Rocket Pharmaceuticals to Present Data from its Fanconi Anemia, Leukocyte Adhesion Deficiency-I and Pyruvate Kinase Deficiency Programs at the 62nd American Society of Hematology Annual Meeting
NEW YORK--(BUSINESS WIRE)-- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a clinical-stage company advancing an integrated and sustainable pipeline
About this update from Rocket Pharmaceuticals, Inc.
[{"type":"text","content":" NEW YORK--(BUSINESS WIRE)--\nRocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces presentations at the upcoming 62nd American Society of Hematology (ASH) Annual Meeting being held virtually December 5-8, 2020. There will be two oral presentations highlighting clinical data from the Fanconi Anemia (FA) and Leukocyte Adhesion Deficiency-I (LAD-I) programs as well as a poster presentation highlighting preliminary clinical data from the Pyruvate Kinase Deficiency (PKD) program. All three programs utilize Rocket's \"Process B\" manufacturing platform.\n\nDetails for Rocket’s presentations are as follows:\n\nOral Presentations\nTitle: Gene Therapy for Fanconi Anemia, Complementation Group A: Updated Results from Ongoing Global Clinical Studies of RP-L102\nSession Title: Gene Editing, Therapy and Transfer I\nPresenter: Agnieszka Czechowicz, M.D., Ph.D., Assistant Professor of Pediatrics, Division of Stem Cell Transplantation, Stanford University School of Medicine\nSession Date: Monday, December 7, 2020\nSession Time: 11:30 a.m. - 1:00 p.m. (Pacific Time)\nPresentation Time: 12:15 p.m. (Pacific Time)\n\nTitle: Phase 1/2 Study of Lentiviral-Mediated Ex-Vivo Gene Therapy for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I): Results from Phase 1\nSession Title: Gene Editing, Therapy and Transfer I\nPresenter: Donald Kohn, M.D., Professor of Microbiology, Immunology and Molecular Genetics, Pediatrics (Hematology/Oncology), Molecular and Medical Pharmacology, and member of the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at the University of California, Los Angeles\nSession Date: Monday, December 7, 2020\nSession Time: 11:30 a.m. - 1:00 p.m. (Pacific Time)\nPresentation Time: 12:30 p.m. (Pacific Time)\n\nPoster Presentation\nTitle: Lentiviral Mediated Gene Therapy for Pyruvate Kinase Deficiency: A Global Phase 1 Study for Adult and Pediatric Patients\nSession Title: Gene Editing, Therapy and Transfer: Poster II\nPresenter: José Luis López Lorenzo, M.D., Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain\nSession Date: Sunday, December 6, 2020\nSession Time: 7:00 a.m. – 3:30 p.m. (Pacific Time)\n\nAbout Fanconi Anemia\nFanconi Anemia (FA...